GLPG
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Galapagos and Gilead entered a binding agreement to collaborate on a T cell engager programMar 31, 2026
- Galapagos and Gilead entered advanced discussions to collaborate on a first-in-class T cell engager program for autoimmune diseasesMar 24, 2026
- Galapagos NV announces FDA grants RMAT designation to GLPG5101 for relapsed/refractory mantle cell lymphomaAug 6, 2025
- Galapagos presents new data from ATALANTA-1 Cohort 3 showing high complete response and MRD negativity with CAR-T candidate GLPG5101 in relapsed/refractory indolent NHLJun 20, 2025
- Galapagos announces oral presentations at EHA and ICML 2025 featuring promising new data from the ATALANTA-1 study of investigational CAR-T candidate GLPG5101.May 14, 2025